- BBIO stock erupts after shattering expectations and rivals in dwarfism study | Investor Business DailyInvestor Business Daily
- BridgeBio Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Growth Velocity of 3.03 cm/yr with No Treatment-Related Adverse EventsYahoo finance
- BridgeBio treatment for genetic cause of dwarfism accelerates growth in small studySTAT
- BridgeBio Stock Rebounds 50% on New Dwarfism Therapy DataMarketWatch
- BBIO stock soars after phase 2 data for achondroplasia candidate (NASDAQ: BBIO)Looking for Alpha